Abbott Reports Q1 Results, Updates 2026 Guidance Following Exact Sciences Acquisition
Abbott Laboratories reported first-quarter earnings, meeting expectations and completing the acquisition of Exact Sciences. Growth was driven by the company's medical device and established pharmaceuticals segments.
Abbott Laboratories announced its first-quarter 2026 financial results, achieving its earnings per share target and completing the acquisition of Exact Sciences. The company reported first-quarter sales of $11.2 billion, a 3.7% increase on a comparable basis, driven by strong performance in Medical Devices and Established Pharmaceuticals.
The Medical Devices segment saw comparable sales grow by 8.5%, while Established Pharmaceuticals reported a 9.0% increase. Diagnostics sales rose 1.8% on a comparable basis, with notable growth in cancer diagnostics following the integration of Exact Sciences. Nutrition sales were impacted by prior strategic pricing actions, and the company expects improved volume growth for the segment later in the year.
Abbott has updated its full-year 2026 guidance, projecting comparable sales growth between 6.5% and 7.5%. The company now forecasts adjusted diluted earnings per share to be in the range of $5.38 to $5.58, reflecting a $0.20 dilution from the Exact Sciences acquisition.
The company also highlighted its product pipeline advancements. Abbott shared positive early results from studies for its Amulet 360 Left Atrial Appendage Occluder for stroke risk reduction and its FreeStyle Libre 3 system for diabetes management. Furthermore, a collaboration with AtaCor Medical is underway to develop next-generation implantable cardioverter-defibrillators.